Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate (as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2007) chronic obstructive pulmonary disease (COPD) and:~  1. Smoking history of at least 10 pack-years.~ 2. Forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 50% of the predicted normal value.~ 3. Post-bronchodilator FEV1/Force vital capacity (FVC) \< 0.7.~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening.~* Patients who have had a respiratory tract infection within 6 weeks prior to screening.~* Patients with concomitant pulmonary disease.~* Patients with alpha-1-antitrypsin deficiency.~* Patients with contraindications for tiotropium treatment.~* Patients with a history of hypersensitivity to any of the study drugs or to drugs from similar drug classes.~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg-tiotropium 18 μg-placebo (Type: EXPERIMENTAL): Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Tiotropium 18 μg-placebo-indacaterol 150 μg (Type: EXPERIMENTAL): Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Placebo-indacaterol 150 μg-tiotropium 18 μg (Type: EXPERIMENTAL): Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).